We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$958M
AUM Growth
+$3.46M
Cap. Flow
+$6.87M
Cap. Flow %
0.72%
Top 10 Hldgs %
27.27%
Holding
97
New
7
Increased
32
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.5M
2
MDT icon
Medtronic
MDT
+$8.92M
3
TECH icon
Bio-Techne
TECH
+$7.15M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.83M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.66M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$11M
3
UNH icon
UnitedHealth
UNH
+$8.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.62M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Industrials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
26
Inspire Medical Systems
INSP
$1.73B
$15.4M 1.6%
61,000
-2,000
-3% -$426K
MCK icon
27
McKesson
MCK
$103B
$14.6M 1.53%
39,000
-11,000
-22% -$4.1M
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
$14.4M 1.5%
230,000
+20,000
+10% +$1.33M
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.6M 1.42%
300,000
+102,933
+52% +$6.66M
DHR icon
30
Danaher
DHR
$147B
$13.3M 1.38%
56,400
-13,536
-19% -$3.14M
HRMY icon
31
Harmony Biosciences
HRMY
$2.27B
$13.2M 1.38%
240,000
+3,000
+1% +$165K
ABT icon
32
Abbott
ABT
$188B
$12.8M 1.34%
117,000
– –
EW icon
33
Edwards Lifesciences
EW
$53B
$10.7M 1.12%
144,000
+19,000
+15% +$1.46M
SILK
34
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10.4M 1.08%
195,871
+40,871
+26% +$1.99M
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$10.3M 1.08%
200,000
-20,000
-9% -$1.06M
NBIX icon
36
Neurocrine Biosciences
NBIX
$16.8B
$10.2M 1.06%
85,000
+2,000
+2% +$234K
CYTK icon
37
Cytokinetics
CYTK
$10.5B
$9.91M 1.03%
216,322
+6,322
+3% +$272K
SWAV
38
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$9.66M 1.01%
47,000
+27,000
+135% +$6.83M
OM icon
39
Outset Medical
OM
$91.4M
$9.3M 0.97%
24,000
+1,333
+6% +$376K
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.21M 0.96%
430,000
+65,000
+18% +$1.39M
IMCR icon
41
Immunocore
IMCR
$1.73B
$8.56M 0.89%
150,000
– –
PODD icon
42
Insulet
PODD
$9.91B
$8.54M 0.89%
29,000
– –
RPRX icon
43
Royalty Pharma
RPRX
$25.8B
$8.5M 0.89%
215,000
– –
PRVA icon
44
Privia Health
PRVA
$2.86B
$8.4M 0.88%
370,000
+93,000
+34% +$2.59M
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$8.34M 0.87%
783,519
+50,000
+7% +$581K
BIIB icon
46
Biogen
BIIB
$30.6B
$8.31M 0.87%
30,000
-2,782
-8% -$786K
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.09M 0.84%
438,000
+50,000
+13% +$1.14M
XNCR icon
48
Xencor
XNCR
$1.6B
$7.66M 0.8%
294,076
– –
TECH icon
49
Bio-Techne
TECH
$11.2B
$7.46M 0.78%
+90,000
New +$7.15M
IMGN
50
DELISTED
Immunogen Inc
IMGN
$7.44M 0.78%
1,500,000
+400,000
+36% +$2.17M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rhenman & Partners Asset Management held 97 positions worth $958M, up 0.36% from $955M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q4 2022 filing shows 7 new, 32 increased, 18 reduced and 4 closed positions. Its largest new stake was Bio-Techne: 90,000 shares worth $7.46M. The largest sale was Abiomed Inc, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q4 2022 buy was Bio-Techne: 90,000 shares worth $7.46M.
  • Rhenman & Partners Asset Management added most to HCA Healthcare in Q4 2022, an estimated $10.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2022 reduction was Intuitive Surgical, cutting an estimated $11M.
  • Rhenman & Partners Asset Management fully exited Abiomed Inc in Q4 2022, selling an estimated $21.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $958M portfolio in Q4 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 4 in Q4 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 0.36% quarter-over-quarter to $958M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.